Q1 Earnings Forecast for CRGX Issued By William Blair

CARGO Therapeutics, Inc. (NASDAQ:CRGX) – Equities researchers at William Blair issued their Q1 2025 EPS estimates for CARGO Therapeutics in a research note issued on Monday, January 13th. William Blair analyst S. Corwin forecasts that the company will earn ($0.95) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for CARGO Therapeutics’ current full-year earnings is ($3.73) per share. William Blair also issued estimates for CARGO Therapeutics’ Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.95) EPS and Q4 2025 earnings at ($0.83) EPS.

A number of other brokerages have also weighed in on CRGX. Chardan Capital reissued a “buy” rating and issued a $28.00 target price on shares of CARGO Therapeutics in a research report on Wednesday, November 13th. HC Wainwright restated a “buy” rating and set a $33.00 price objective on shares of CARGO Therapeutics in a research report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $31.80.

CARGO Therapeutics Price Performance

Shares of NASDAQ:CRGX opened at $11.18 on Wednesday. CARGO Therapeutics has a 1 year low of $10.91 and a 1 year high of $33.92. The company has a market cap of $514.59 million, a P/E ratio of -2.62 and a beta of 2.50. The stock’s fifty day moving average price is $16.10 and its 200-day moving average price is $17.69.

CARGO Therapeutics (NASDAQ:CRGX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.26.

Institutional Investors Weigh In On CARGO Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CRGX. Rhumbline Advisers grew its position in CARGO Therapeutics by 14.0% during the second quarter. Rhumbline Advisers now owns 30,639 shares of the company’s stock valued at $503,000 after buying an additional 3,765 shares during the period. JPMorgan Chase & Co. grew its position in shares of CARGO Therapeutics by 74.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,007 shares of the company’s stock valued at $277,000 after acquiring an additional 6,426 shares during the period. Bank of New York Mellon Corp increased its stake in shares of CARGO Therapeutics by 11.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 69,171 shares of the company’s stock worth $1,136,000 after purchasing an additional 7,146 shares in the last quarter. MetLife Investment Management LLC raised its holdings in CARGO Therapeutics by 59.3% in the 3rd quarter. MetLife Investment Management LLC now owns 19,833 shares of the company’s stock worth $366,000 after purchasing an additional 7,380 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in CARGO Therapeutics by 437.8% during the third quarter. BNP Paribas Financial Markets now owns 11,438 shares of the company’s stock valued at $211,000 after purchasing an additional 9,311 shares in the last quarter. Hedge funds and other institutional investors own 93.16% of the company’s stock.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.